We are live on ! Find out more
ZNTL icon

Zentalis Pharmaceuticals
ZNTL

106 hedge funds and large institutions have $1.29B invested in Zentalis Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 48 increasing their positions, 30 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

6,496% more call options, than puts

Call options by funds: $1.58M | Put options by funds: $24K

150% more funds holding in top 10

Funds holding in top 10: 2 → 5 (+3)

60% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 30

9.54% more ownership

Funds ownership: 103.2% → 112.74% (+9.5%)

2% more capital invested

Capital invested by funds: $1.27B → $1.29B (+$27.5M)

12% less funds holding

Funds holding: 120 → 106 (-14)

70% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 20

Holders
106
Holders Change
-14
Holders Change %
-11.67%
% of All Funds
1.7%
Holding in Top 10
5
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+150%
% of All Funds
0.08%
New
6
Increased
48
Reduced
30
Closed
20
Calls
$1.58M
Puts
$24K
Net Calls
+$1.56M
Net Calls Change
-$2.23M

Top Buyers

1
Capital International Investors
Capital International Investors
California
+$65.6M
2
APM
Avidity Partners Management
Texas
+$19.9M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$10.7M
4
SI
Sofinnova Investments
California
+$9.05M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$7.3M

Top Sellers

1
Axa
Axa
France
-$4.96M
2
WP
Woodline Partners
California
-$3.73M
3
AAA
Affinity Asset Advisors
New York
-$3.68M
4
NIP
Nicholas Investment Partners
California
-$3.44M
5
Walleye Capital
Walleye Capital
New York
-$1.85M
Name Holding Trade Value Shares
Change 		Change in
Stake
MCMC
1
Matrix Capital Management Company
New Hampshire
$185M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$159M +$7.3M +339,570 +4%
APM
3
Avidity Partners Management
Texas
$104M +$19.9M +926,900 +22%
Vanguard Group
4
Vanguard Group
Pennsylvania
$83.8M +$1.16M +53,888 +1%
Wellington Management Group
5
Wellington Management Group
Massachusetts
$72.9M +$10.7M +496,129 +16%
BlackRock
6
BlackRock
New York
$69.9M +$2.93M +136,113 +4%
State Street
7
State Street
Massachusetts
$62.1M +$5.03M +233,963 +8%
Capital International Investors
8
Capital International Investors
California
$61.4M +$65.6M +3,048,182 New
TCM
9
Tybourne Capital Management
Hong Kong
$44.9M -$1.51M -70,344 -3%
T. Rowe Price Investment Management
10
T. Rowe Price Investment Management
Maryland
$44.5M +$38.1K +1,773 +0.1%
T. Rowe Price Associates
11
T. Rowe Price Associates
Maryland
$43.8M -$883K -41,040 -2%
EAM
12
Eventide Asset Management
Massachusetts
$43.4M +$6.36M +295,515 +16%
DCMIC
13
Decheng Capital Management III (Cayman)
Cayman Islands
$36.7M – – –
AllianceBernstein
14
AllianceBernstein
Tennessee
$27.5M +$723K +33,614 +3%
Federated Hermes
15
Federated Hermes
Pennsylvania
$24.4M +$2.69M +125,000 +12%
Primecap Management
16
Primecap Management
California
$22.8M -$1.07M -49,530 -4%
SI
17
Sofinnova Investments
California
$20.2M +$9.05M +420,688 +72%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$17.3M +$452K +21,007 +3%
IHAM
19
Integral Health Asset Management
New York
$15.1M +$4.3M +200,000 +36%
Capital World Investors
20
Capital World Investors
California
$13.8M – – –
Citadel Advisors
21
Citadel Advisors
Florida
$12.8M +$1.83M +84,919 +15%
Northern Trust
22
Northern Trust
Illinois
$8.46M +$64.6K +3,002 +0.7%
Allspring Global Investments
23
Allspring Global Investments
North Carolina
$7.95M -$13.6K -633 -0.2%
Goldman Sachs
24
Goldman Sachs
New York
$7.86M +$1.12M +52,050 +15%
Charles Schwab
25
Charles Schwab
California
$6.76M +$264K +12,254 +4%
1
2 3 4 5

ZNTL Hedge Fund Activity: Q4 2022 in Review

106 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q4 2022, worth a combined $1.29B — up 2.2% from $1.27B a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of ZNTL and 6 opened new positions — a net loss of 14 holders — while 30 trimmed existing stakes and 48 added.

The largest buyer was Capital International Investors, opening a new position worth an estimated $65.6M. The largest seller was Axa, exiting entirely with an estimated $4.96M sold.

  • 106 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q4 2022, down from 120 in Q3 2022.
  • Funds reported $1.29B of Zentalis Pharmaceuticals stock for Q4 2022, up 2.2% quarter-over-quarter.
  • 6 funds opened new Zentalis Pharmaceuticals positions in Q4 2022 and 20 closed out, a net change of -14 holders.
  • The largest Zentalis Pharmaceuticals buyer in Q4 2022 was Capital International Investors, an estimated $65.6M added.
  • The largest Zentalis Pharmaceuticals seller in Q4 2022 was Axa, an estimated $4.96M sold.

Based on aggregated 13F filings for Q4 2022.